Analysts Set Expectations for MiMedx Group Q1 Earnings

MiMedx Group, Inc (NASDAQ:MDXG) – Equities researchers at Northland Securities issued their Q1 2026 EPS estimates for shares of MiMedx Group in a note issued to investors on Thursday, February 26th. Northland Securities analyst C. Byrnes forecasts that the company will earn ($0.03) per share for the quarter. The consensus estimate for MiMedx Group’s current full-year earnings is $0.30 per share. Northland Securities also issued estimates for MiMedx Group’s Q3 2026 earnings at $0.03 EPS, Q4 2026 earnings at $0.04 EPS and FY2026 earnings at $0.04 EPS.

MiMedx Group (NASDAQ:MDXG) last posted its quarterly earnings data on Wednesday, February 25th. The company reported $0.14 EPS for the quarter, topping the consensus estimate of $0.09 by $0.05. MiMedx Group had a net margin of 11.60% and a return on equity of 29.37%. The business had revenue of $118.10 million for the quarter, compared to analyst estimates of $106.78 million.

Several other research firms also recently commented on MDXG. Citizens Jmp started coverage on MiMedx Group in a report on Monday, February 23rd. They issued a “market outperform” rating and a $10.00 target price on the stock. Cantor Fitzgerald cut their price objective on shares of MiMedx Group from $12.00 to $8.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 17th. Citigroup started coverage on shares of MiMedx Group in a research note on Monday, February 23rd. They set a “market outperform” rating for the company. UBS Group set a $10.00 target price on shares of MiMedx Group in a research note on Monday, February 23rd. Finally, Lake Street Capital reduced their price target on shares of MiMedx Group from $12.00 to $10.00 and set a “buy” rating for the company in a research report on Tuesday, January 20th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $9.60.

MiMedx Group Stock Performance

Shares of MDXG opened at $4.76 on Monday. The company has a quick ratio of 3.92, a current ratio of 4.32 and a debt-to-equity ratio of 0.06. The stock has a market cap of $707.19 million, a P/E ratio of 14.88 and a beta of 1.60. The business’s 50 day moving average price is $5.61 and its 200-day moving average price is $6.54. MiMedx Group has a 52 week low of $4.71 and a 52 week high of $8.30.

Institutional Investors Weigh In On MiMedx Group

A number of hedge funds have recently added to or reduced their stakes in the stock. First Light Asset Management LLC boosted its stake in shares of MiMedx Group by 89.5% in the 3rd quarter. First Light Asset Management LLC now owns 3,652,952 shares of the company’s stock worth $25,498,000 after buying an additional 1,725,458 shares during the last quarter. Nantahala Capital Management LLC purchased a new position in MiMedx Group in the third quarter worth about $10,237,000. Marshall Wace LLP grew its stake in shares of MiMedx Group by 864.9% during the 4th quarter. Marshall Wace LLP now owns 1,381,288 shares of the company’s stock valued at $9,351,000 after purchasing an additional 1,238,132 shares during the period. Hillsdale Investment Management Inc. purchased a new stake in shares of MiMedx Group during the 4th quarter valued at about $7,134,000. Finally, Disciplined Growth Investors Inc. MN lifted its stake in shares of MiMedx Group by 283.0% in the 3rd quarter. Disciplined Growth Investors Inc. MN now owns 1,383,451 shares of the company’s stock worth $9,656,000 after purchasing an additional 1,022,202 shares during the period. 79.15% of the stock is currently owned by hedge funds and other institutional investors.

MiMedx Group Company Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.